Biliary Tract Carcinoma Clinical Trial
Official title:
Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma.
To evaluate the efficacy and safety of irinotecan hydrochloride liposome injection combined with Capecitabine for second-line treatment in Patients With advanced or metastatic biliary tract carcinoma.
Status | Not yet recruiting |
Enrollment | 20 |
Est. completion date | December 31, 2025 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. The patient had good compliance, could understand the research process of this study, and signed a written informed consent. 2. Age =18 years. 3. Has histologically confirmed diagnosis of advanced (metastatic) and/or unresectable (locally advanced) biliary tract cancer (intra-or extrahepatic cholangiocarcinoma or gallbladder cancer). 4. Subjects who had received gemcitabine prior first-line therapy and had not received fluorouracil drugs. 5. Subjects who have progressed after receiving previous first-line therapy, relapse within 6 months after the end of (neo) adjuvant therapy is considered as first-line therapy failure. 6. Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST 1.1). 7. ECOG (Eastern Cooperative Oncology Group) performance status of 0-2. 8. Has a life expectancy of greater than 3 months. 9. LVEF=50%. 10. Appropriate organ function is defined as follows: (Hematology and blood biochemistry tests must be completed within 14 days prior to enrollment, and the following criteria are met): 1. ANC =1.5×10^9/L 2. Hb=90g/L 3. PLT =100×10^9/L 4. total bilirubin =1.5 x ULN 5. ALT/AST = 2.5 x ULN; When there is liver metastasis, ALT/AST = 5 x ULN 6. Serum creatinine (Cr) =1.5×ULN or creatinine clearance (CCr) =50mL/min (according to Cockcroft-Gault fórmula) 7. Coagulation function: prothrombin time (PT), activated partial thromboplastin time (APTT) and international standardized ratio (INR) =1.5×ULN 11. Patients with biliary obstruction should receive adequate biliary drainage. 12. Adverse reactions caused by previous treatment must be restored to grade 1 or baseline according to CTCAE5.0 (except for toxicity such as alopecias, grade 2 and below peripheral neuropathy, which can be included after the investigator determines that there is no safety risk). 13. non-pregnant or lactating female; Effective contraception should be used by female/Male of childbearing age during the study period and for 6 months after the end of study treatment. 14. There were no contraindications for the use of irinotecan liposomes and capecitabine. Exclusion Criteria: 1. Patients who have had other malignant tumors within the previous 5 years (except cured carcinoma in situ and skin basal cell carcinoma). 2. Uncontrolled pleural effusion or ascites. 3. Any known brain or meningeal metastases. 4. Subjects were co-administering a potent CYP3A4 inducer within 3 weeks prior to first dosing, or a potent CYP3A4 inhibitor or a potent UGT1A1 inhibitor within 3 weeks prior to first dosing. 5. Subjects underwent large organ surgery (except needle biopsy, central venous catheterization, port catheterization, stenting for relief of biliary obstruction, percutaneous hepatobiliary drainage, and cholecystostomy) or an elective surgical program within 4 weeks before the first dose of the study drug. 6. Active, uncontrolled bacterial, viral, or fungal infections with systemic treatment, defined as persistent signs/symptoms associated with infection that do not go away despite the use of appropriate antibiotics, antiviral therapy, and/or other treatment, including patients with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV). 7. Patients who are known to have dihydropyridine dehydrogenase (low activity) or deficiency. 8. There are serious concomitant diseases: such as uncontrolled diabetes after hypoglycemic drug treatment, uncontrolled hypertension, serious cardiovascular and cerebrovascular disease, kidney failure, liver failure, uncontrolled epilepsy, central nervous system disease or mental disorder history, clear gastrointestinal bleeding tendency, intestinal paralysis, intestinal obstruction, etc. 9. Grade 1 diarrhea with an increase in the number of stools > 4 times per day compared to baseline; The moderate and severe effluents from stoma increased; Limited activities of daily living with the aid of tools or even self-rational activities of daily living; Life-threatening; Need urgent medical attention. 10. Had participated in other clinical investigators within 4 weeks before enrollment. 11. Unsuitable for participation in the trial by the investigator assessed. |
Country | Name | City | State |
---|---|---|---|
China | Peking Union Medicalcollege Hospital | Beijing |
Lead Sponsor | Collaborator |
---|---|
Ba Yi | CSPC Ouyi Pharmaceutical Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free survival (PFS) | To evaluate the efficacy of anti-tumor | baseline up to approximately 6 months | |
Secondary | Objective response rate (ORR) | To evaluate the efficacy of anti-tumor | baseline up to approximately 6 months | |
Secondary | Overall survival (OS) | To evaluate the efficacy of anti-tumor | baseline up to approximately 12 months | |
Secondary | Quality of life (QoL) | To identify the quality of life by QLQ-C30(V3.0) | baseline up to approximately 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04003896 -
A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT04003636 -
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)
|
Phase 3 | |
Not yet recruiting |
NCT05064852 -
A Real-world Study of the Safety and Efficacy of Surufatinib in the Treatment of Biliary Tract Carcinoma
|
||
Recruiting |
NCT05668884 -
GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma
|
Phase 2 | |
Recruiting |
NCT05123482 -
A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02151084 -
A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer
|
Phase 2 | |
Recruiting |
NCT06048133 -
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
|
Phase 2 | |
Recruiting |
NCT05845554 -
Application of Chromosomal Instability in Early Diagnosis of Biliary Tract Carcinoma
|
||
Completed |
NCT00490399 -
Trial of Gemcitabine and Cisplatin in Patients With Inoperable Biliary Tract Carcinomas
|
Phase 2 | |
Completed |
NCT04067960 -
Pharmacogenomics Testing in Directing the Optimal Use of Supportive Care Medications in Patients With Stage III-IV Cancer
|
Early Phase 1 | |
Withdrawn |
NCT02105350 -
A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer
|
Phase 1 | |
Recruiting |
NCT06047990 -
Endobiliary Percutaneous Cryobiopsy in Malignant Biliary Obstruction
|
N/A | |
Active, not recruiting |
NCT04924062 -
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study
|
Phase 3 | |
Not yet recruiting |
NCT06463548 -
Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma
|
N/A | |
Terminated |
NCT04178460 -
A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment
|
Phase 1 | |
Completed |
NCT03027284 -
A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06199882 -
SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT05023109 -
GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC
|
Phase 2 | |
Not yet recruiting |
NCT06168292 -
Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma
|
N/A | |
Recruiting |
NCT04979663 -
GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer
|
Phase 1/Phase 2 |